Annexon, Inc. (ANNX): who owns it and who trades it
As of Nov 16, 2026, ANNX insiders reported 9 open-market sales worth $286K and 13 purchases worth $12.4M in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Ted Yednock (Vice president), with $70.3K. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Annexon
From the latest filingsOverall: about as much buying as selling. Funds, insiders and famous investors were close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns ANNX
216 funds and institutions reported ANNX shares worth $1B at the end of Q2 2026. The largest holder is FMR LLC (Fidelity) with $111M.
10 largest owners, by value
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| FMR LLC (Fidelity) | 19.52M | – | $111M | +84% |
| BlackRock, Inc. | 13.54M | – | $77.3M | +24% |
| Redmile Group, LLC | 11.87M | – | $67.8M | -18% |
| State Street Corp | 9.82M | – | $56.1M | +42% |
| Bvf Inc | 8.70M | – | $49.7M | No change |
| Woodline Partners LP | 6.93M | – | $39.5M | +196% |
| Vanguard Capital Management LLC | 6.87M | – | $39.2M | +15% |
| Mak Capital One LLC | 5.86M | – | $33.5M | +24% |
| Goldman Sachs Group Inc | 5.83M | – | $33.3M | +171% |
| Siren, L.L.C. | 4.46M | – | $25.5M | +13% |
| Bain Capital Life Sciences Investors, LLC | 4.44M | – | $25.3M | -15% |
| Bellevue Group AG | 4.10M | – | $23.4M | -21% |
| Geode Capital Management, LLC | 4.04M | – | $23.1M | +20% |
| Mpm Bioimpact LLC | 3.54M | – | $20.2M | – |
| Ameriprise Financial Inc | 3.51M | – | $20M | +2% |
| Great Point Partners LLC | 3.50M | – | $20M | +40% |
| Adage Capital Partners Gp, L.l.c. | 3.50M | – | $20M | -19% |
| Morgan Stanley | 3.14M | – | $18M | +15% |
| Palo Alto Investors LP | 2.95M | – | $16.8M | No change |
| Balyasny Asset Management L.P. | 2.83M | – | $16.2M | -27% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, ANNX insiders reported $12.4M of open-market purchases and $286K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 24, 2026 | Douglas Love | CEO | Purchase | 26,065 | $3.83 | $99.8K | Form 4 |
| May 28, 2026 | Muneer A Satter | Director | Purchase | 613,497 | $5.41 | $3.3M | Form 4 |
| May 11, 2026 | William H. Carson | Director | Purchase plan | 8,000 | $5.78 | $46.2K | Form 4 |
| Apr 10, 2026 | William H. Carson | Director | Purchase plan | 8,000 | $6.20 | $49.6K | Form 4 |
| Mar 10, 2026 | William H. Carson | Director | Purchase plan | 8,000 | $5.67 | $45.4K | Form 4 |
| Mar 2, 2026 | Jamie Dananberg | CHIEF MEDICAL OFFICER | Sale | 5,820 | $5.43 | $31.6K | Form 4 |
| Mar 2, 2026 | Michael Overdorf | Vice president | Sale | 4,339 | $5.42 | $23.5K | Form 4 |
| Mar 2, 2026 | Ted Yednock | Vice president | Sale | 5,566 | $5.42 | $30.2K | Form 4 |
| Mar 2, 2026 | Dean Richard Artis | Vice president | Sale | 5,894 | $5.43 | $32K | Form 4 |
| Mar 2, 2026 | Jennifer Lew | CFO | Sale | 5,565 | $5.42 | $30.2K | Form 4 |
| Feb 18, 2026 | Dean Richard Artis | Vice president | Sale | 5,290 | $5.10 | $27K | Form 4 |
| Feb 18, 2026 | Ted Yednock | Vice president | Sale | 7,857 | $5.11 | $40.1K | Form 4 |
| Feb 18, 2026 | Michael Overdorf | Vice president | Sale | 6,225 | $5.10 | $31.7K | Form 4 |
| Feb 18, 2026 | Jennifer Lew | CFO | Sale | 7,851 | $5.11 | $40.1K | Form 4 |
| Dec 30, 2025 | William H. Carson | Director | Purchase plan | 4,115 | $5.02 | $20.7K | Form 4 |
| Dec 1, 2025 | Jung Choi | Director | Purchase | 33,000 | $4.19 | $138K | Form 4 |
| Dec 1, 2025 | William H. Carson | Director | Purchase plan | 4,115 | $4.47 | $18.4K | Form 4 |
| Nov 21, 2025 | Muneer A Satter | Director | Purchase | 422,613 | $4.28 | $1.8M | Form 4 |
| Nov 20, 2025 | Muneer A Satter | Director | Purchase | 400,000 | $4.48 | $1.8M | Form 4 |
| Nov 19, 2025 | Muneer A Satter | Director | Purchase | 500,000 | $3.94 | $2M | Form 4 |
| Nov 18, 2025 | Muneer A Satter | Director | Purchase | 500,000 | $3.18 | $1.6M | Form 4 |
| Nov 17, 2025 | Muneer A Satter | Director | Purchase | 500,000 | $2.99 | $1.5M | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Muneer A Satter | Director | $12M | – | May 28, 2026 |
| William H. Carson | Director | $180K | – | May 11, 2026 |
| Jung Choi | Director | $138K | – | Dec 1, 2025 |
| Douglas Love | PRESIDENT AND CEO, Director | $99.8K | – | Sep 24, 2026 |
| Ted Yednock | EVP & CHIEF INNOVATION OFFICER | – | $70.3K | Mar 2, 2026 |
| Jennifer Lew | EVP & CHIEF FINANCIAL OFFICER | – | $70.3K | Mar 2, 2026 |
| Dean Richard Artis | EVP & CHIEF SCIENTIFIC OFFICER | – | $59K | Mar 2, 2026 |
| Michael Overdorf | EVP & CHIEF BUSINESS OFFICER | – | $55.3K | Mar 2, 2026 |
| Jamie Dananberg | CHIEF MEDICAL OFFICER | – | $31.6K | Mar 2, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
ANNX short interest
28.98M ANNX shares are sold short. Over the last 12 reports the number of shares short went up 19%.
As of Oct 30, 2026, 28.98M ANNX shares were sold short, down 8.4% from the report before. At the average daily volume of 4.03M shares, buying them all back would take about 7.2 trading days (days to cover).
Shares short
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 28.98M | – | -8% | 4.03M | 7.2 |
| Oct 15, 2026 | 31.63M | – | -1% | 3.07M | 10.3 |
| Sep 30, 2026 | 32.01M | – | -3% | 3.60M | 8.9 |
| Sep 15, 2026 | 32.87M | – | +2% | 2.81M | 11.7 |
| Aug 31, 2026 | 32.09M | – | -2% | 2.52M | 12.7 |
| Aug 14, 2026 | 32.58M | – | +6% | 2.47M | 13.2 |
| Jul 31, 2026 | 30.77M | – | +3% | 2.94M | 10.4 |
| Jul 15, 2026 | 29.83M | – | +1% | 5.19M | 5.7 |
| Jun 30, 2026 | 29.60M | – | +12% | 5.46M | 5.4 |
| Jun 15, 2026 | 26.39M | – | +2% | 2.84M | 9.3 |
| May 29, 2026 | 25.83M | – | +6% | 2.65M | 9.7 |
| May 15, 2026 | 24.29M | – | +4% | 1.83M | 13.3 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Annexon company events
Annexon filed 11 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 9, 2026.
- Nov 9, 2026ResultsReleased financial results. Filing
- Aug 12, 2026AnnouncementThe Company issued a press release titled “Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy to Add Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch Open-Label Extension Study.” A copy of the press release is attached as Exhibit 99.2 to this Current… Filing
- Aug 10, 2026LeadershipMuneer Satter, a member of the board of directors of Annexon, Inc., notified the Company of his resignation as a member of the Board and as a member of the audit committee of the Board and as chair of the nominating and corporate governance committee of the Board, effective immediately prior to the… Filing
- Aug 6, 2026AnnouncementAnnexon, Inc. issued a press release titled “Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week.” A copy of the press release is attached as Exhibit 99.1 to this Current… Filing
- Jul 30, 2026AgreementAnnexon, Inc. entered into a Loan and Security Agreement with Oxford Finance LLC, as collateral agent (in such capacity, the “Collateral Agent”), and certain lenders from time to time party thereto. Filing
- Jun 12, 2026VoteReported shareholder vote results. Filing
- May 7, 2026ResultsReleased financial results. Filing
- Mar 30, 2026ResultsReleased financial results. Filing
- Feb 17, 2026LeadershipThomas G. Wiggans, Chairman of the Board of Directors of Annexon, Inc., notified the Company of his intent to retire as a member of the Board and therefore not stand for reelection at the Company’s 2026 annual meeting of stockholders. Filing
- Jan 14, 2026AnnouncementShared information with investors. Filing
- Jan 12, 2026AnnouncementAnnexon, Inc. issued a press release titled “Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026” announcing its 2026 strategic priorities and key milestones for its lead programs. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Famous investors that hold ANNX
4 of the 50 well-known investors we track reported holding ANNX in their latest 13F filing. The largest position is Steve Cohen's, worth $14.3M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Steve Cohen · Point72 Asset Management | Q3 2026 | 3.38M | $14.3M | 0.0% | +145% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 1.13M | $4.8M | 0.0% | +90% |
| Israel Englander · Millennium Management | Q3 2026 | 340,950 | $1.4M | 0.0% | -71% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 197,300 | $835K | 0.0% | -57% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named ANNX in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | BIOTECHNOLOGY VALUE FUND L P | 13G/A | 2.3% |
| Nov 16, 2026 | BIOTECHNOLOGY VALUE FUND L P | 13G/A | 2.3% |
| Nov 5, 2026 | FMR LLC | 13G/A | 13.9% |
| Nov 5, 2026 | FMR LLC | 13G/A | 13.9% |
Questions about Annexon, Inc. (ANNX) stock
Who owns the most ANNX stock?
The largest reported owner of Annexon, Inc. (ANNX) is FMR LLC (Fidelity). In total, 216 funds and institutions reported holding ANNX at the end of Q2 2026. See the largest owners.
Are ANNX insiders buying or selling?
In the last 12 months, ANNX insiders reported 13 open-market purchases worth $12.4M and 9 sales worth $286K. The latest trade was on Sep 24, 2026. See every trade.
What is the short interest in ANNX?
As of Oct 30, 2026, 28.98M ANNX shares were sold short, down 8.4% from the report before. At the average daily volume of 4.03M shares, buying them all back would take about 7.2 trading days (days to cover). See the history.
Which famous investors hold ANNX?
4 of the 50 well-known investors we track reported ANNX in their latest 13F filing, including Steve Cohen, Ken Griffin, Israel Englander. The largest position is worth $14.3M. See all holders.
Executive pay
Annexon's chief executive was paid a total of $3.6M for the year ended Dec 31, 2025, down 3% from $3.7M the year before. In the last 12 months, Annexon's executives and directors bought $12.4M of stock on the open market and sold $286K.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.